MustGrow Biologics and Sumitomo Corporation Announce Extension of Exclusive Agreement and Program Advancement

Research, News, and Market Data on MustGrow Biologics

• Sumitomo Corporation has extended the option for exclusive testing with MustGrow’s technology for preplant soil fumigation, bioherbicide, postharvest and food preservation for potatoes, and bananas in North, Central, and South America.
• Sumitomo Corporation continues to demonstrate positive levels of efficacy utilizing MustGrow’s technology in comparison to synthetic chemical standards.
• Sumitomo Corporation to continue driving all field development, including regulatory and market assessment work necessary for commercialization.

TOKYO,
JAPAN & SASKATOON, SK, CANADA – August 17, 2022 – Sumitomo Corporation
(TYO: 8053) (OTC: SSUMY) and MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF)
(FRA: 0C0) (“MustGrow”) have signed an extension to their Exclusive Evaluation and Option Agreement (the “Extension
Agreement”) to continue developing MustGrow’s mustard-based technology across the Americas.

Pursuant to the Extension Agreement, MustGrow has granted Sumitomo Corporation the exclusive right to continue developing MustGrow’s mustard-based technologies for preplant soil fumigation, bioherbicide, and postharvest and food preservation for potatoes and bananas in North, Central, and South America for an additional option period (the “Extension
Period”). Over the span of the initial option period, Sumitomo Corporation’s evaluation efforts demonstrated positive levels of efficacy utilizing MustGrow’s technology in comparison to certain synthetic chemical standards. These positive tests, conducted across the Americas, resulted in the parties’ desire to extend the term of the Exclusive Evaluation and Option Agreement. During the Extension Period, Sumitomo Corporation plans to continue to drive all field development, regulatory and market assessment work necessary for commercialization.

The global crop protection chemicals market size was valued at USD 63.7 billion in 2020, and is projected to reach a value of USD 74.1 billion by 2025.⁽¹⁾ The growth of this market is attributed to the increasing need for food security of the growing global population. A large growth market is biopesticides, which are pesticides produced naturally, with minimum usage of chemicals. Due to rising environmental concerns and awareness of the pollution potential and health hazards of many synthetic conventional pesticides, the demand for biopesticides has been rising steadily in all parts of the world.

SUMITOMO CORPORATION COMMENT

“We are convinced that BioSolutions combined with AgTech are the future of agriculture and fundamental pillars where we are focusing our investment in the development of new solutions. After evaluating and verifying the effectiveness of the MustGrow technology in different crops with different application techniques, we are very glad to take a step forward in the collaboration with MustGrow.”

“We expect to strengthen this collaboration to accelerate the development to make this safe and effective tool available to farmers as soon as possible for a more sustainable agriculture,” said Marcos Mares, Head of Global Business Development in Sumitomo Corporation AgriScience Department.

MUSTGROW COMMENT

“We are very excited to have Sumitomo Corporation commit to the next stage of our agreement. Considering that close to 45% of the global food is produced in North, Central and South America, it is critical to continue to innovate and develop technologies like ours,” said Corey Giasson, MustGrow’s President & CEO. “Having an organization like Sumitomo Corporation demonstrate the benefits in field and commit to move forward with our technologies is a great step to providing a sustainable solution for farmers globally.”

Source 1 – https://www.marketsandmarkets.com/Market-Reports/crop-protection-380.html

About
Sumitomo Corporation

 Sumitomo Corporation (“SC”) is a leading Fortune 500 global trading and business investment company with 131 locations (Japan: 20, Overseas: 111) in 66 countries and regions. The entire SC group consists of more than 900 companies. SC conducts commodity transactions in all industries utilizing worldwide networks, provides customers with financing, serves as an organizer and a coordinator for various projects, and invests in companies to promote greater growth potential. SC’s core business areas include six business units: Metal Products; Transportation & Construction Systems; Infrastructure; Media & Digital; Living Related & Real Estate; and Mineral Resources, Energy, Chemical & Electronics, and one initiative: Energy Innovation.

SC began exporting business of crop protection products in the 1970s, and has expanded its business realm to importing and wholesaling in 37 countries with 40 companies. Leveraging these broad networks and its long experience in the industry, SC has further expanded its activities to make a multifaceted contribution to global agriculture, such as the direct sales of agricultural inputs to farmers and the utilization of cutting-edge agricultural technologies.

For more information, please visit: https://www.sumitomocorp.com/en/jp.

About
MustGrow

MustGrow is an agriculture biotech company developing organic biopesticides and bioherbicides by harnessing the natural defense mechanism of the mustard plant to protect the global food supply from diseases, insect pests, and weeds. MustGrow and its leading global partners — Janssen (pharmaceutical division of Johnson & Johnson), Bayer, Sumitomo Corporation, and Univar Solutions’ NexusBioAg — are developing mustard-based organic solutions to potentially replace harmful synthetic chemicals. Over 100 independent tests have been completed, validating MustGrow’s safe and effective approach to crop and food protection. Pending regulatory approval, MustGrow’s patented liquid products could be applied through injection, standard drip or spray equipment, improving functionality and performance features. Now a platform technology, MustGrow and its global partners are pursuing applications in several different industries from preplant soil treatment and weed control, to postharvest disease control and food preservation. MustGrow has approximately 49.2 million basic common shares issued and outstanding and 55.1 million shares fully diluted. For further details, please visit www.mustgrow.ca.

MustGrow
Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: (i) potential product approvals; (ii) anticipated actions by partners to drive field development work including dose rates, application frequency, application methods, and the regulatory work necessary for commercialization; (iii) expected product efficacy of MustGrow’s mustard-based technologies; and (iv) expected outcomes from collaborations with commercial partners.

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) the preferences and choices of agricultural regulators with respect to product approval timelines; (ii) the ability of MustGrow’s partners to meet obligations under their respective agreements; and (iii) other risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2021 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

© 2022 MustGrow Biologics Corp. All rights reserved. 

Wednesday, August 17, 2022

Ayala Pharmaceuticals (AYLA)
RINGSIDE Data Presentation Announced With 2Q Results

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Financial Loss Was Less Than Expected.  Ayala reported 2Q22 loss of $ 8.2 million or $(0.54) per share, compared with our estimated loss of $10.9 million or $(0.71) per share.  The difference was largely due research and development spending of $5.6 million coming in lower than our estimate of $8.2 million.  Cash on hand at the end of the quarter was $20.1 million.

Phase 2/3 RINGSIDE Trial Data Presentation Planned At ESMO.  In July, Ayala announced preliminary findings from the Phase 2/3 RINGSIDE trial testing AL102 in desmoid tumors.  As discussed in our note from July 6, the company reported encouraging results although no data was released.  It stated that the trial had shown sufficient tumor activity, safety, and reiterated plans to initiate Phase B later in the year. The data presentation is now planned for the meeting of the European Society for Medical Oncology (ESMO) to be held September 9-13 in Paris, France. …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

BioSig’s Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhythm Symposium 2022

News and Market Data on BioSig Technologies

August 17, 2022

Leading Medical Center of Excellence Physician will discuss
integrating the PURE EP™ System into their practice and procedural workflow

Westport, CT, Aug. 17, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced  its participation in the Kansas City Heart Rhythm Symposium, being held on August 20-21, 2022. The Company’s PURE EP ™ System,  a non-invasive device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology, will be highlighted in a physician presentation during the symposium.

The presentation, titled, “Going Back to Old School –
Leveraging EGMs to Improve Efficacy, Safety of Ablation” will be conducted during a symposium session beginning at 12:30 PM ET on Sunday, August 21, 2022. Hicham El Masry. M.D., a Cardiac Electrophysiologist at Mayo Clinic’s Arizona Campus, will discuss the clinical advantages of the PURE EP™ System and the impact the technology has made on his electrophysiology (EP) practice and procedural workflow.  

During the event, the Company’s clinical and commercial teams will host product demonstrations that will showcase the latest advancements and software features of its PURE EP ™ System. The Company will also provide an update on developments in its clinical pipeline. 

“We are looking forward to returning to KCHRS, with the latest advancements of the PURE EP™ System that have been demonstrated and featured by one of our earliest adopters,” commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc. “We would like to thank Dr. Lakkireddy for allowing us to be a part of such an important meeting and Dr. El Masry for representing our technology at the symposium.”

To
register for the event, please click here.

BioSig recently announced the commencement of a physician-initiated research protocol that will analyze the signals acquired by its PURE EP™ System during Radiofrequency (RF) ablation. Led by Dhanunjaya DJ Lakkireddy, MD, Medical Director for the Kansas City Heart Rhythm Institute, the single center study underway at Overland Park Regional Medical Center, is officially registered with clinicaltrials.gov [NCT05464537], and includes 30 participants with paroxysmal atrial fibrillation (AF) undergoing pulmonary vein isolation (PVI).

About
KCHRS 2022
The Kansas City Heart Rhythm Symposium is an EP-focused medical education event for the neighboring four state regions. A variety of topics will provide specialists and generalists an update on the evolution of disease processes, diagnostic tools, therapeutic strategies and ethical issues in the advancement of patient care. To learn more visit, www.kchrs.com.

About
BioSig Technologies

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP™ System, is a novel signal processing and acquisition platform designed to extract advanced diagnostic and therapeutic data that enhances physician workflow and increases throughput. PURE EP™ was engineered to address the limitations of existing EP technologies by empowering physicians with superior signals and actionable insights.

The Company is in a national commercial launch of the PURE EP™ System. The technology is in regular use in some of the country’s leading centers of excellence, including Mayo Clinic, and Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.

Clinical data acquired by the PURE EP™ System in a multi-center study at centers of excellence including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center  was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP(T.M.) signals over conventional sources.

Forward-looking
Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market conditions and the Company’s intended use of proceeds, (ii) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (iii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iv) difficulties in obtaining financing on commercially reasonable terms; (v) changes in the size and nature of our competition; (vi) loss of one or more key executives or scientists; and (vii) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Andrew Ballou

BioSig Technologies, Inc.

Vice President, Investor Relations

55 Greens Farms Road

Westport, CT 06880

aballou@biosigtech.com

203-409-5444, x133

Image Credit: NIAID (Flickr)

Monkeypox Treatments and Vaccines are Creating Investor Opportunities

Investors are joining healthcare providers and public officials as they all gear up for what is now being called a public health emergency. Monkeypox was a rare disease that has been infecting humans since 1970. The latest global monkeypox outbreak, while significant, has demonstrated the known disease is less of a concern than the novel coronavirus, which made its way to the U.S. in 2020. However, the U.S. President, the WHO, and other global authorities have declared monkeypox an emergency. They have begun stockpiling pills, patches, and vaccines in anticipation of a full-scale effort to prevent the spread.

As authorities declare their intentions, investors are working toward understanding the disease and the likely treatments. From this, they forecast which they expect will be most supported, effectively “the winners.” This list is likely to include everything from antiseptic manufacturers, to contact tracing products, condom manufacturers, and of course, preventatives and treatments. It is the medical side of preventing and treating the diseases that is already getting support from deep-pocket governments.

The virus continues to spread. There were 12,688 confirmed monkeypox cases in the U.S. on Tuesday (August 16), according to the CDC. This is an increase from 9,492 the previous Tuesday. The U.S. has more confirmed cases than any other country. Outside the U.S.,  Brazil, France, Germany, Spain, and the U.K. each also have thousands of monkeypox cases.

Investor’s Attention

Bavarian Nordic (BAVA.CO), a Copenhagen-listed company, is a Danish biotech vaccine manufacturer. The company manufactures the only authorized vaccine against monkeypox in the world. Bavarian Nordic has received an onslaught of requests for supplies of the shot. While they have a monopoly on an approved vaccine, they told Bloomberg today (August 17), “Demand keeps rising, and it’s no longer certain that we can continue to meet the demand we’re facing even with the upgrade of our existing manufacturing site in Denmark.” This could provide investors with additional opportunity if they choose to outsource manufacturing of their Jynneos monkeypox vaccine.

BAVA is up 164% since May 1.

Siga Technologies (SIGA), is a U.S.-based Nasdaq listed company. Siga manufactures a therapy for smallpox that is not yet approved in the U.S. for monkeypox called Tpoxx. Tpoxx has been approved for use for monkeypox in the UK and other affected countries outside the U.S.

SIGA is up 266% since May 1. 

Tonix Pharmaceuticals (TNXP), is a U.S.-based Nasdaq listed company that is developing a live form of the horsepox virus to be used as a preventative for monkeypox and smallpox infections. In January 2020, the company announced the results of test studies in non-human primates that were challenged with monkeypox. In that study, the safety of TNX-801 was exhibited by stable body weights and body temperatures for all treated animals.  

Read the most recent TNXP research
report by Noble Capital Markets.

Take Away

Just a short time ago, investors were made aware of how profitable a declared healthcare crisis can be for companies and their investors. Obviously, those medically impacted benefit as well. While the growing monkeypox outbreak does not pose as large a threat as Covid-19, it provides an interesting opportunity as it is already declared a health threat. The emergency status means there will be significant financial support to curtail and eliminate the outbreak. Learning early where that will be could be profitable

Investors can research small and microcap biotech and pharmaceutical companies on Channelchek by signing-up to have access to the complete website.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content

Is Biotech’s Outperformance Reaching a New Stage of Development?

Why They Use Antibiotics on the Covid Virus

Capitalism versus Coronavirus (May 2020)

Tonix Pharmaceuticals (TNXP) NobleCon18 Presentation Replay

Sources

https://www.whitehouse.gov/briefing-room/press-briefings/2022/08/11/press-briefing-by-white-house-monkeypox-response-team-and-public-health-officials/

https://www.hpnonline.com/infection-prevention/article/21277723/mayo-clinic-expertise-on-monkeypox

https://www.cdc.gov/poxvirus/monkeypox/about.html

https://www.npr.org/sections/health-shots/2022/08/04/1115676160/white-house-declares-monkeypox-a-public-health-emergency

https://www.cdc.gov/poxvirus/monkeypox/sexualhealth/index.html

https://www.pinknews.co.uk/2022/07/16/monkeypox-sexually-transmitted-semen-condom-sex/

https://www.barrons.com/articles/monkeypox-vaccine-supply-bavarian-nordic-51660735711

Stay up to date. Follow us:

Tuesday, August 16, 2022

Cocrystal Pharma (COCP)
2Q Reported With Influenza and COVID-19 Product Updates

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q Included One-Time Charges.  Cocrystal reported a loss of $24.4 million or $(0.25) per share, including a write-off of goodwill for $19.1 million and a legal settlement expense of $1.6 million.  Operating expenses excluding these charges were $3.7 million, compared with our estimated operating expenses of $3.8 million.  The company ended the quarter with $51.0 million in cash.

Influenza Program Reported First Data With More Expected Later in 2022.  The company reported that data from CC-42344, its oral PB2 inhibitor that blocks a polymerase enzyme needed for viral replication.  Data from a single-ascending dose study supporting the once-daily dosing schedule.  Additional results from the Phase 1 study enrolling healthy volunteers in Australia are expected to be announced later this year.   …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.